Wells Fargo & Company Lucid Diagnostics Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 3,463 shares of LUCD stock, worth $2,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,463
Previous 14,505
76.13%
Holding current value
$2,839
Previous $11,000
81.82%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LUCD
# of Institutions
36Shares Held
2.07MCall Options Held
0Put Options Held
0-
Luminus Management LLC Houston, TX726KShares$595,1760.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$459,9500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA204KShares$167,5710.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT126KShares$103,6160.01% of portfolio
-
Ayrton Capital LLC Westport, CT73.9KShares$60,6033.26% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $31.6M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...